Please provide your email address to receive an email when new articles are posted on . The FDA approved expanded labeling for Medtronic’s InterStim II and InterStim Micro sacral neuromodulation ...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., the developer of the first rechargeable Sacral Neuromodulation (r-SNM™) System for the treatment of urinary and fecal ...
Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable sacral neuromodulation (“SNM”) devices for ...
Medtronic (MDT) recently announced that it has received a favorable decision with respect to a long-standing patent dispute related to sacral neuromodulation. Specifically, per Medtronic’s press ...
The battery-free percutaneous sacral neuromodulation system has comparable efficacy to published rates for traditional sacral neuromodulation devices. The US Food and Drug Administration (FDA) has ...
Fewer punctures and shorter surgical time reported for sacral neuromodulation with 3D printing and ultrasound localization. (HealthDay News) — For patients with neurogenic bladder and pelvic ...
Axonics Inc. received FDA approval for its recharge-free sacral neuromodulation (SNM) implantable neurostimulator (INS) for bladder and bowel dysfunction. The F15’s primary cell requires no recharging ...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., developer of miniaturized implantable Sacral Neuromodulation technology, announced today that it has completed a $38.5 million ...
Axonics Modulation Technologies has received premarket approval from the Food and Drug Administration (FDA) for Axonics r-SNM System, an implantable sacral neuromodulation device (SMN), for the ...
Follow-up of patients at a Belgian institution reveals that sacral neuromodulation (SNM) is effective for the treatment of lower urinary tract dysfunction (LUTD) over the long term, but often requires ...
US Medical device giant Axonics has announced that it has secured market clearance from Australia’s Therapeutic Goods Administration (TGA) for its R20 rechargeable sacral neuromodulation (SNM) system ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results